Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vixtimotamab in Myelodysplastic Syndromes
NCT03516591Phase 1Completed
- Sponsor
- Amphivena Therapeutics
- Start
- Jun 2018
- Primary completion
- Jul 2020
- Countries
- 1
01
Overview
Phase 1, open-label trial in myelodysplastic syndromes (MDS) (2 arms), sponsored by Amphivena Therapeutics. Primary endpoints: Dose Limiting Toxicity at 35 days and Overall Response Rate. Started Jun 2018; status: completed.
02
Conditions
myelodysplastic syndromes (MDS)
Beyond the preview
Go deeper on NCT03516591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03516591.